Basic Info
  • Grade: Injection Grade

    Factory Location: No. 369, South Yuzhou Rd. Lianyungang, Jiangsu, China

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Payment Terms: L/L

    Fulvestrant injection, an injection for intramuscular administration,
    is supplied as 250 mg/5 mL fulvestrant.
    It is an an estrogen receptor antagonist indicated
    for the treatment of:
    · Hormone receptor (HR)-positive advanced breast cancer in
    postmenopausal women with disease progression following
    endocrine therapy. (1)
    · HR-positive, HER2-negative advanced or metastatic breast
    cancer in postmenopausal women in combination with
    ribociclib, as initial endocrine based therapy or following
    disease progression on endocrine therapy. (1)
    · HR-positive, HER2-negative advanced or metastatic breast
    cancer in combination with palbociclib or abemaciclib in
    women with disease progression after endocrine therapy

Send your message to this supplier
  • From:
  • To:
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service